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Familial atypical multiple mole-melanoma syndrome 
is characterized by the familial occurrence of malig­
nant melanoma of the skin in combination with multi­
ple atypical precursor nevi; its pattern shows a domi­
nant inheritance in pedigrees. During the last 5 years 
we have performed linkage analysis in seven Dutch 
familial atypical multiple mole-melanoma families to 
define the locus of the underlying gene defect. In 1989 
it was reported that in familial melanoma families in 
the USA a disease-gene was located on chromosome 
lp. However, in the Dutch families we could exclude 
this chromosome from harboring the Dutch familial 
atypical multiple mole-melanoma gene. Very recently 
a new candidate locus was found on chromosome 9p, 
which could be confirmed in our family material. A 
A !though the familial occurrence of melanoma has been known for many decades, the remarkable phenotype accompanying the hereditary variant of melanoma was only recognized in 1978 and was then named the B-K mole syndrome by Clark et al [1] and the familial 
atypical multiple mole-melanoma (FAMMM) syndrome by Lynch 
et al [2]. The phenotypic corner stone of the syndrome is called 
dysplastic nevus and therefore the syndrome is also known as the 
familial type of the dysplastic nevus syndrome (DNS) [3]. In 1980, 
when dysplastic nevi were recognized to occur in the general popu­
lation, individuals showing dysplastic nevi and lacking a family 
history of melanoma were diagnosed as having the sporadic type of 
DNS. One or more sporadic dysplastic nevi are reported to occur in 
5 - 18% of the general population [4,5]. There are apparently no 
differences between both the sporadic and familial phenotypes. The 
term dysplastic has been criticized because pathologists and clini­
cians have various concepts and definitions of the word. Further­
more the specificity of the histologic criteria that have been recom­
mended to identify dysplastic nevi is being questioned by some 
investigators and the clinicopathologic correlation is far from 100% 
[6,7]. In earlier publications we have reported our histologic criteria 
for diagnosing dysplastic nevi. These criteria are quite inclusive: 
features of architectural and cytologic atypia should be present, as 
well as features of a host response [8,9]. With regard to this ongoing 
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nevus syndrome; F AMMM, familial atypical multiple mole-melanoma syn­
drome; Rh, Rhesus locus. 
melanoma-associated gene was linked to several 
markers on chromosome 9p21. In a linkage analysis in 
which only melanoma patients were considered as af­
fected, marker D9S171 showed a maximum lod score 
of3.11 (theta 0.0). After introducing family members 
with 10 or more, or five or more, atypical nevi as af­
fected in addition to the melanoma patients, the maxi­
mum lod score rose to 4.88 (theta 0.05) and 3.79 (theta 
0.07), respectively. Interestingly, the sharing of a 
unique chromosome 9p21 haplotype among most 
melanoma patients in the families from two different 
villages suggests that an old common mutation is 
present in the Leiden region. Key words: dysplastic nevi/ 
early diagnosis of melanoma/management of cancer famities.] 
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debate it seems preferable to refer to these large, easily recognized 
nevi as clinically atypical nevi [10] . These terms are also useful in 
epidemiologic studies. Clinically atypical nevi are usually multiple, 
flat, or completely macular moles, which considerably vary from 
each other, thus constituting the distinct moly pattern. Atypical 
nevi can be recognized by several features of which the following 
five are usually mentioned: a size of 5 mm or larger, hazy indistinct 
borders, variations in pigmentation, asymmetry of shape, and a red, 
vascular hue or erythema [11]. 
For familial melanoma and atypical nevi the term FAMMM syn­
drome satisfies the designation of the genetic context of the dis­
order. During the last 5 years we have performed linkage analyses in 
seven Dutch FAMMM families to define the locus of the underly. 
ing gene defect. We encountered problems regarding the definition 
of the affected phenotype, because the FAMMM syndrome shows a 
considerable amount of variance in phenotypes, from most evi­
dently affected persons with atypical mole-counts over 100, to per­
sons showing very few atypical nevi and even no atypical nevi at all. 
The non-penetrance rate (under the assumption of dominant inhere 
itance) was somewhere between 10 and 20%. To be used in linkage 
analyses various models were defined, varying from melanoma only 
to various combinations of melanoma and atypical nevi, reflecting 
the FAMMM phenotype. A second problem was the occurrence of 
frequent sporadic phenocopies (one or more atypical nevi) in the 
pppulation. . 
'. Most investigators studying pedigrees with the FAMMM syn­
drome came to the conclusion that the condition shows a dominant 
pattern of inheritance with, on the average, 40 -50% of children of 
affected individuals being gene carriers themselves [12-14]. How­
ever, arguments against autosomal dominant inheritance were 
presented by Happle and coworkers [15], who suggested polygenic 
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Table I. Characteristics (age and number) of Living Affected and Unaffected Individuals in 10 Pedigrees 
Melanoma 
FAMMMmoles 
(dysplastic nevi) 
Non-Penetrant 
Obligate Gene 
Carriers 
No 
Abnormalities 
Mean age (years) 
Range 
38.4 22.8 54.3 26.8 
11-70 
241 
16-68 11-74 32-74 
Number of Individuals 37 (19)b 123 27 r-----187 gene carriers (169)' I 
428 investigated individuals (410)' I 
• Figures in parentheses have been corrected for bias of ascertainment (reproduced with permission from Bergman W, Gruis NA, Frants RR: Cytogenet Cell GeneI69:161, 1992). 
inheritance. In a summary of Genetic Analysis Workshop 7 on 
familial melanoma in October 1990, it was concluded that domi­
nant inheritance for familial melanoma was strongly rejected. Dif­
ferences in segregation models, methods of ascertainment correc­
tion, and differences in the definition of affected were held 
responsible for this conclusion [16]. 
Till now the combination of melanoma and/or one or more 
atypical nevi as the disease phenotype in linkage analyses, yielded 
conflicting results. The observed linkage in the vicinity of Rh and 
PND [17,18] on the short arm of chromosome 1 could not be 
reproduced by several other groups. In fact the entire region re­
ported to contain the combined melanoma and atypical nevi suscep­
tibility locus has been statistically excluded in these studies [19 -22]. 
Recently, Cannon-Albright et al [23] have localized a gene predis­
posing for melanoma to chromosome 9p21. In their analysis, only 
patients with melanoma were regarded as affected, whereas the 
OCcurrence of atypical nevi was ignored. Also in 26 Australian fami­
lies this chromosome 9p linkage could be confirmed with only 
melanoma as the affected phenotype [24]. We now seem to be 
dealing with two types ofFAMMM syndromes, one with a disease 
gene on chromosome Ip and one with a melanoma-associated gene 
on chromosome 9p. 
THE DUTCH FAMMM FAMILY MATERIAL 
In 1982 the Pigmented Lesions Clinic of the Department of Der­
matology of Leiden University Hospital was established, facilitat­
ing studies on FAMMM syndrome. Ten families were found in 
which at least three members had melanoma of the skin and several 
family members showed atyyical nevi, validating the diagnosis of 
the FAMMM syndrome [25J . All families were from the region of 
Leiden and lived within a distance of 50 km from the hospital. Five 
of the ten families were from the same coastal fishing village K and 
three came from a village R, 20 km north east of Leiden. The 
cluster-villages seem to have in common the fact that the affected 
families have lived there for many generations because of strong 
family ties. However, no common ancestor was found going back to 
1800, when the governmental registries were begun. The total 
number of individuals (affected or at risk) in the 10 pedigrees was 
534, 428 of which were seen at our Pigmented Lesions Clinic [26]. 
Forty six individuals did not attend and 60 individuals were dead at 
the start of the investigation. Characteristics (age and number) of 
living affected and unaffected individuals can be found in Table I 
[26]. 
Nevi were considered clinically atypical if they showed three or 
more of the following five criteria: size 5 mm or larger, asymmetric 
shape, irregular pigmentation, hazy border, and erythema. The 
total number of atypical nevi was counted and categorized as fol­
lows: 1-4,5-9 and 10 or more atypical nevi. It is important to 
realize that these figures do not represent total mole-counts; these 
numbers refer to the number of nevi that could be recognized as 
being clinically atypical according to the above mentioned criteria. 
Included in the most recent linkage study were the most relevant 
sections of seven of the ten original pedigrees, including 156 indi­
viduals [27]. Figures of the pedigrees have been reported elsewhere 
[27]. These subjects have been screened regularly over periods vary­
ing from 7 -11 years. Twenty-nine subjects with at least one mela­
noma were present within the selected pedigree parts. In 94% of the 
apparently affected individuals one or more atypical nevi were re­
moved during the years of follow-up, in all cases verifying the 
clinical diagnosis, using the histologic criteria we published earlier 
[8,9]. In 50% of the melanoma patients less than five atypical nevi 
were recognizable, which indicates that also lower nevus counts can 
eventually lead to the development of a melanoma. For the study of 
chromosome 1, linkage studies using polymorphic markers were 
carried out on 96 individuals from six of our 10 families. Technical 
details can be found elsewhere [19]. The analysis included as af­
fected individuals melanoma patients and family members showing 
at least one atypical nevus. It was decided to focus on the short arm 
of chromosome 1 to confirm or reject the reported loose linkage 
with the rhesus locus (Rh) (chromosome 1 p34) reported by Green et 
al [18] and the strong positive lod score data concerning chromo­
some 1 p36 reported by Bale et al [17]. In Table D the markers we 
used have been summarized [19]. Together this panel of eight poly­
morphic markers completely spans the short arm of chromosome 1. 
Later, linkage studies were carried out on DNA from 156 subjects 
from seven of our 10 families. A total of 124 microsatellite markers, 
TableD. Lod Scores for Linkage Between FAMMM and Marker Loci on the Short Arm of Chromosome 1" 
Regional 
Recombination Fraction (0) 
Exclusion 
Locus Localization 0.01 0.10 0.20 0.30 0.40 cMb 
DNF15S1 Ip36.3 -5.06 -2.47 -1.07 -0.39 -0.08 12 
DIZ2 Ip -5.91 -3.51 -1.73 -0.76 -0.25 16 
RH Ip34 -17.24 -6.98 -2.80 -0.96 -0.27 23 
FUCAl Ip34 -6.05 -2.44 -0.97 -0.33 -0.07 12 
D1S17 Ip31-pter -6.75 -3.63 -1.62 -0.62 -0.12 18 
D1S57 Ip -6.27 -4.74 -3.12 -1.61 -0.60 27 
PGMI Ip22.1 -3.82 -2.10 -0.25 +0.09 +0.14 11 
PND Ip36 -6.00 -2.38- -1.14 -0.50 -0.18 13 
• Reproduced with permission; Van Haeringen et 41: Genomics 5:365, 1989. 
I cM, centiMorgans definitely excluded on either side of the tested marker, assuming lod scores of -2 or less as definitive proof from exclusion; F AMMM gene frequency 0.003; life 
rime penetrance 85%. 
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Table m. Maximum Two-Point lod Scores Between Three 9p21 Markers and Various Models ofFAMMM 
A B C D 
Melanoma Melanoma Melanoma Melanoma 
Model Only and/or> 10 AN" and/or> 5 AN" and/or> 1 AN" 
Marker 
INFA 
D9S1 71 
D9S126 
1.43 (0.08) 
3.11 (0.00 ) 
2.76 (0.03) 
2.07 (0.07) 
4.88 (0.05) 
2.91 (0.04) 
• AN. atypical nevi; in brackets are the recombination fractions at maximum lod score. 
mostly (CA)n repeat markers, were analyzed by performing multi­
plex polymerase chain reactions on all individual DNA samples. 
The complete list oElocus numbers and physical map locations have 
been published elsewhere [26]. As no significant positive lod score 
throughout the genome had been found, we focused on the recently 
reported candidate region on chromosome 9p . Table m summa­
rizes the results we obtained in this region. To begin with, linkage 
analyses were carried out assuming the existence of a single mela­
noma-predisposing gene with dominant action and incomplete 
penetrance (model A). The occurrence of atypical nevi in family 
members was initially ignored. In subsequent analyses the occur­
rence of atypical nevi was also considered as a manifestation of the 
disease gene. In three consecutive steps, subjects with more than 10 
clinically atypical nevi (model B), with more than 5 (model C), and 
with any clinically atypical nevi (model D) were included in the 
analyses as potential gene carriers. Technical and biostatistical de­
tails can be found elsewhere [27]. 
RESULTS 
In Table II the markers used to investigate chromosome 1 for 
harboring the FAMMM gene, have been summarized [19,22,27]. 
As can be seen, Rh yields a strong negative lod score for all recombi­
nation frequencies, allowing exclusion of23 centiMorgans (eM) on 
either side of the marker. Also other markers gave negative lod 
scores; PND was the particular marker that revealed the very high 
lod score in the study by Bale et al. Our combined linkage data thus 
definitely exclude the Dutch FAMMM gene from the short arm of 
chromosome 1. 
In Table m the results of three major markers used to investigate 
chromosome 9 have been summarized [27]. Several models men­
tioned in the methods section have been tested. In model A (includ­
ing only melanoma patients as affected) the highest lod scores were 
reached in testing marker D9S1 71 (peak lod score of 3.11) and 
D9S126 (peak lod score of 2.76). Model B (including melanoma 
patients and family members with more than 10 atypical nevi as 
affected) yielded a significantly higher lod score (lod score 4.88). 
Also model C yielded a higher maximum lod score than model A. 
The model including milder manifestations (model D) yielded less 
support. Lod scores were also calculated separately for each family 
and it appeared that all families contributed to the combined maxi­
mum lod score. 
Haplotypes for eight consecutive chromosome 9 markers 
(D9S162, IFNA, D9S126, D9S171, D9S104, D9S52 , D9S43) were 
constructed in the seven families (Table IV). Families 1, 3, and 4 , 
are from village K, whereas families 6, 10, and 19 are from village R. 
Family 7 originates from a different area (the city of U) . As can be 
seen in Table IV the consensus haplotype 2-6-3-8-2-3-6 is shared 
by most of the melanoma patients in the families from village K, 
whereas the consensus haplotype 7 -3-2-8-2-3-6 is shared by most of 
the melanoma patients in the families from village R. Between the 
families from K and R the consensus 8-2-3-6 is present. Family 7 
from the city ofU has a totally different haplotype.t 
t Gruis NA, Sandkuijl LA, Bergman W, Frants R: Com on haplotype in 
Dutch FAMM  families (submitted for publication). 
0.90 (0.14) 
3.7 9 (0.07) 
1.2 8 (0. 13) 
DISCUSSION 
0.0  (0.50) 
1.87 (0.12) 
2.09 (0.00) 
The possible relationship between atypical nevi and melanoma 
roughly falls into three categories: 1) The two phenotypes are com­
pl�tely unrelated. The high prevalence of atypical nevi in the popu­
latlOn leads to the frequent coincidental finding of atypical nevi in 
families with multiple subjects with melanoma. 2) The atypical 
nevus phenotype is predisposing to the development of melanoma. 
3) Atypical nevi and melanoma are pleiotropic effects of one and the 
same gene. The first mentioned possibility is, in our opinion, the 
l�ast probable. Although atypical nevi seem to occur in the popula­
no� very fr�quently, reporte� per�entages up to 18% [5], atypical 
neVI occur in melanoma panents in percentages up to 50% [28]. 
Moreover case-control studies have indicated the atypical nevus to 
be one of the major risk factors for sporadic and familial melanoma 
with a relative risk of 90 respectively, 440 in a recent study from 
Scotland [29] . In those pedigrees reported to have linkage to the 
short arm of chromosome 1, most of the linkage evidence was based 
upon persons with atypical nevi, rather than the melanoma pheno­
typ� [17]. Ve
.
ry rec�ntly the same investigators were able to verify 
therr results in a different group of falnilies, which validate their 
earlier observations [30]. In these falnilies we find arguments for a 
close relati?nship between atypical nevi and melanoma, both phe­
notypes bemg caused by one gene-defect (possibility number 3). In 
the Utah pedigrees something different seems to be going on. The 
linkage results on chromosome 9p are very strong and these results 
have been obtained exclusively on melanoma-affected family mem­
bers [20]. The Utah group has investigated all kinds of models 
reflecting the disease phenotype, some being very elaborate includ­
ing total nevus density (total sum of nevus area divided by the total 
body surface area) [31] . None of these models yielded higher lod 
scores than those obtained by including melanoma patients only 
(personal communication, Skolnick M). 
These results provide arguments for a multi-gene etiology, the 
melanoma-associated gene being located on chromosome 9p and 
the locus of the atypical nevus gene still to be defined. In light of 
these considerations our linkage results are surprising and perhaps 
even more confusing. Using a model with only melanoma as the 
phenotype of interest, we detected linkage to the same chromo­
soma11ocation as in the Utah families. Introducing into the analysis 
family members with the more classical FAMMM phenotype with 
more than 10 atypical nevi the lod score significantly rose. How-
; 
'Table IV. Haplotype Analysis Among Melanoma Patients 
From Seven FAMMM Families. Using Eight Consecutive 
Chromosome 9p21 Markers (098162. IFNA, 09S126. 
098171.098104.09852.09843) 
Family Village Haplotype Consensus 
1 K 2 638236 8236 
3 K 261 9534 3 
4 K 2638236 8236 
6 R 732 8236 8 236 
10 R 7328236 8 236 
19 R 7338-36 8 36 
7 U 10355 6 35 3 
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ever, by introducing phenotypes with one to five atypical nevi, the 
lod score dropped; the evidence for linkage disappearing almost 
entirely. Obviously, by introducing these mild phenotypes into the 
analysis we seem to introduce too many false positive individuals 
(phenocopies) for the lod score to persist. Still, it is too simple to 
regard the presence of only few atypical nevi as insignificant because 
more than 50% of the melanoma patients in our families only 
showed one to five atypical nevi. One could argue that an age-re­
lated effect could have negatively influenced the numbers of atypi­
cal nevi since melanoma patients tended to be somewhat older than 
family members with atypical nevi only. In our analysis we tried to 
correct for age effects by introducing two age categories: younger or: 
older than 40' years. Significant differences in melanoma risk be� 
tween the two groups and the three different categories of nevus 
counts could not be shown [27]. 
We conclude that in the Dutch FAMMM families a dominant 
gene on chromosome 9p21 plays a critical role in the predisposition 
to familial melanoma and that the presence of more than 10, or 
perhaps more than 5, clinically atypical nevi seems to be the more 
critical FAMMM phenotype. In the next few years isolation of the 
gene will eventually allow DNA diagnosis of all family members 
with few or no atypical nevi. Finally it will be possible to focus 
screening exclusively on proven gene carriers, and herewith to con­
tribute to the arrest of melanoma development and mortality. Addi­
tional studies are needed in order to define the relationship between 
atypical nevi and melanoma in more detail, and to establish the 
minimal number of atypical nevi required for an increased mela­
noma risk. 
It was very interesting to find a consensus haplotype in the fami­
lies from village K and R, whereas it was not possible to ascertain 
common ancestry back to 1800. The distance between villages K 
and R is 24 km, several ages ago these villages were connected by 
water. These facts suggest that a centuries-old mutation exercised its 
influence in these families, carrying death and destruction through 
the generations. The finding of sharing of the haplotypes suggests 
that we might be dealing with a common mutation in these fami­
lies. Furthermore the occurrence of recombinants allows a consider­
able reduction of the genomic region under investigation, which is 
advantageous in the process of isolation of the gene. One more 
unsettled question about the FAMMM syndrome is whether an 
increased risk of ocular melanoma and systemic cancers goes with 
the syndrome as we have advocated [32-35]. It is hoped also that 
this dilemma will be solved as the 9p gene has been isolated and 
characterized in the near future. 
REFERENCES 
1. Clark WH, Reimer RR, Greene MH, Ainsworth AM, Mastrangelo MJ: Origin of 
familial malignant melanomas from heritable melanocytic lesions. Arch Derma­
toI114:732-738, 1978 
2. Lynch HT, Frichot BC, Lynch]F: Familial atypical multiple mole-melanoma 
syndrome.] MeJ Genet 15:352-356,1978 
3. Kramer K: Dysplastic nevi as precursors to hereditary melanoma.] Demu//ol Surg 
OncoI9:619-622, 1983 
4. Roush GC, Barnhill RL, Duray PH, Titus LJ, EmstofF MS, Kirkwood JM: Diag­
nosis of dysplastic nevus in difFerent populations.] Am Acad Derma/o114:419-
425, 1986 
5. Augustsson A, Stiemer U, Rosdahl I, Suurknla M: Melanocytic naevi in sun 
exposed and protected skin in melanoma patients and controls. Acto Derm 
VenereoI7:S12-S17,1990 
6. De Wit PEJ, Van 't Hof-Grootenbroer B, Ruiter DJ, Bondi R, Brocker E-B, 
Cesarini JP, Hastrup N, Hou-Jensen K, MacKie RM, SchefFer E, Suter L, Urso 
C: Validity of the histopathologica1 criteria used £or diagnosing dysplastic 
naevi. Bur] Cancer 6:831-839.1993 
7. Duncan LM, Berwick M, BruijnJA, Byers HR, Mihm C. Barnhill L: Histopatho­
logic recognition and grading of dysplastic melanocytic nevi: an interobserver 
agreement study.] InlltSt DermatoI100:318S -321S, 1993 
8. Steijlen PM, Bergman W, Hermans J, SchefFer E, Vloten van WA, Ruiter DJ: 
The efficacy of histopathological criteria required for diagnosing dysplastic 
nevi. HlstopathoI12:289-300, 1988 
LINKAGE RESULTS OF DUTCH FMMM FAM1LlES 125S 
9. Ruiter DJ, Steijlen PM, Bergman W, Scheffer E: Premalignant and borderline 
melanocytic lesions. Eur J Cancer Clin Onco124:S15 -S22. 1988 
10. Schneider JS, Moore DH, Sagebiel RW: Melanoma predicted by clinically atypi­
cal moles. Lanat 339:1492, 1 992 
11. Bergman W, Fusaro RM: Precursor lesions to melanoma. Clin Derma/o19:1-9, 
1992 
12. Bale SJ, Chakravarti A, Greene MH: Cutaneous malignant melanoma and famil­
ial dysplastic nevi: evidence for autosomal dominance and pleiotropy. Am] 
Hum Genet 38:188-196.1986 
13. Bergman W, Palan A, Went LN: Clinical and genetic studies in six Dutch 
kindreds with the dysplastic nevus syndrome. Ann Hum Genet 50:249-258. 
1986 
14. Lynch HT, Fusaro RM, Johnson LR, Lynch]F: Hereditary malignant melanoma 
and the FAMMM syndrome. In: Lynch HT, Fusaro RM (eds.). Heretiitory Ma­
lignant Melanoma. CRC press, Boca Raton, 1991. pp 1-24 
15. Traupe H. Macher E, Hamm H, Happle R: Mutation rate estimates are not 
compatible with autosomal dominant inheritance of the dysplastic nevus "syn­
drome." Am]MedGenet32:155-157,1989 
16. Risch N. Sherman S: Genetic analysis workshop 7: summary of the melanoma 
workshop. CanurGenet Cy/ogenet 59:148-158,1992 
17. Bale SJ, Dracopoli NC. Tucker MA, Clark WH. Fraser MC, Stanger BZ. Green 
P, Doris-Keller H, Housman DE, Greene MH: Mapping the gene for hetedi­
tary cutaneous malignant melanoma-dysplastic nevus to chromosome lp. N 
BnglJ Med 320:1367 -1372. 1989 
18. Greene MH, Goldin LR, Clark WH, Lovrlen E, Kraemer KH, Tucker MA, Elder 
DE, Fraser MC, Rowe S: Familial cutaneous malignant melanoma: autosomal 
dominant trait possibly linked to the Rhesus locus. Proc Natl Acad Sci USA 
80:6071-6075.1983 
19. Haeringen van A, Bergman W, Nelen MR, Kooij-Meijs van der E, Hendrikse A, 
Wijnen]H, Meera Khan P, Klasen EC, Frants RR: Exclusion of the dysplastic 
nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage 
studies in Dutch families. Genomics 5:61-64,1989 
20. Cannon-Albright LA, Goldgar DE, Wright EC: Evidence against the reported 
linkage of the cutaneous melanoma-dysplasia nevus syndrome locus to chro­
mosome 1p36. Am] Hum Genet 46:912 - 918, 1 990 
21. NancarrowDJ, WaikerGJ, WeberJL, Waiters MK,Palmer JM,Hayward NK: 
Linkage mapping of melanoma (MLM) using 172 microsatellite markers. Ge­
nomics 14:939-947, 1992 
22. Gruis NA, Bergman W, Frants RR: Locus for susceptibility to melanoma on 
chromosome lp (letter). N Engl] Med 322:853-854,1990 
23. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Foun­
tain JE, Hegi ME, Wiseman RW, Petty EM, Bale AE, Olopade 01, Diaz MO. 
KwiatkowskiDJ,PiepkomMW,Zone JJ,SkoluickMH:Assignmentof alocus 
for familial melanoma (MLM) to chromosome 9p13-p22. Science 258:1148-
1152,1992 
24. Nancarrow DJ, Mann GJ, Holland EA, Walker GJ, Beaton SC, Walters MK, 
Luxford C. Palmer lM, Donald JA. Weber JL. Fountain lW. Kefford RF, 
Hayward NK: Confirmation of chromosome 9p linkage in familial melanoma. 
Am] Hum Genet 53:916-942.1993 
25. Bergman W. Haeringen van A, Went LN: The FAMMM syndrome in the Neth­
erlands. In: Lynch HT, Fusaro RM (eds.). Hereditary MalignantMelanoma. CRC 
Press Inc, Boca Raton, 1991, pp 35-52 
26. Bergman W, Gruis NA, Frants RR: The Dutch FRAMMM family material: 
clinical and genetic data. Cytogenet Cell Genet 59:161-164, 1992 
27. Gruis NA, Sandkuijl LA, Weber JL, Zee van der A. BorgsteinA-M, Bergman W, 
Frants RR: Linkage analysis in Dutch FRAMMM syndrome families; effect of 
nevus count. Melanoma Res 3:271-279, 1993 
28. Kramer KH, Tucker M, Tarone R. Elder DE, Clark WH: Risk of cutaneous 
melanoma in dysplastic nevus syndromes type A and B. New Bngl] Med 
25:1615, 1986 
29. Mackie RM. McHenry P, Hole D: Accelerated detection with prospective sur­
veillance for cutaneous malignant melanoma in high risk groups. Lanat 
341:1618-1620, 1993 
30. Goldstein AM, Dracopoli NC. Ho EC, Fraser MC, Kearns KS, Bale SJ, McBride 
OW: Further evidence for a locus for cutaneous malignant melanoma-dysplas­
tic nevi (CMM/DN) on chrornosome 1 p. and evidence for genetic heterogene­
ity. Am] Hum Genet 52:537-550,1993 
31. Goldgar DE, Cannon-Albright LA. Meyer LJ, Piepkom MW. Zone JJ. Skolnick 
MH: Inheritance of nevus number and size in melanoma and dysplastic nevus 
syndrome kindreds.] Natl Cancer Inst 83:1726-1733,1991 
32. Vasen HPA, Bergman W, Haeringen van A, SchefFer E, Sloten van AB: The 
familial dysplastic nevus syndrome. Natural history and the impact of screening 
on prognosis. Bur] Cancer Clin OncoI25:337-341, 1989 
33. Bergman W, Watson P, de Jong J, Lynch HT. Fusaro RM: Systemic cancer and 
the PAMMM syndrome. Br] Canw 61:932-936,1990 
34. Vink J. Gruis NA, Mooy eM, Bergman W. Oosterhuis JA, Went LN: Ocular 
melanoma in families with dysplastic nevus syndrome.] Am Acad Dermatol 
23:858-862,1990 
35. Oosterhuis IN, Went LN, Lynch HT: Primary choroidal and cutaneous mela­
noma-bilateral choroidal melanomas and familial ocCUrtence of melanomas. Br 
] Ophthalmol 66:230-233. 198 2 
